A Next-Generation, Efficient, Fully Automated, High-Definition 3D Patient Treatment Verification System for Stereotactic Radiation Therapy,Radiosurgery and Particle Therapy

The GoalTo improve patient safety and outcomes for all modalities of external beam radiation therapy in a cost effective manner by using a new type of HDD pre treatment Patient Specific Quality AssurancePSQAProduct to be Developed by the end of Phase IIThe CrystalBallSystemwill consist of a fully robotized fast laser CT of low cost reusable radiochromic polymer gel dosimetersIt will detect and correct all significant errors accumulated during treatment planning delivery that would likely be missed by existing QA toolsExisting Paradigms and Clinical Practices Being Challengedcurrent emphasis on device performance QA rather than process QAinadequate density of data sampling in measured QA dose distributions inDHealth Relatedness of the ProjectTheCrystalBallwill be able topredict the futuresuccess or failure of a patient s radiotherapy treatmentRoutine use of this product will lower cancer care costs associated with avoidable recurrences and complications that lead to costly readmissionsdisabilitiesand premature deathCritical Barrier to Progress inD Polymer Gel Dosimetry Being AddressedPersistent lack of a commercial polymer gel dosimetry package that is not only accurate but also cost effective and time efficientPhase I Specific AimsFeasibility of Critical Technological Innovationsnovel reusable radiochromic polymer gel dosimeter with instant dose response and stable signalthermally reversible and resettable overnightsuitable for cost effective daily PSQA usageAlso optically chemically compatible with selectedD printing materialsnovel design of a cost effectivefast laser CT scanner for imagingD dose distributions in polymer gel dosimetersnovelD autocalibration algorithm based on dose response modelingenabling a time efficient single scan PSQA protocolnovel algorithm for autosegmentation of multi PTV dose distribution data and for autogeneration of QA reports for individual PTVswith application to single isocenter VMAT treatment of multiple brain metastasesnovel software interface for HDD QA analysis with detailedanalysis options triggered only by suboptimalD gamma passing rates and or other global metricsAimsandwill be tested at a leading radiation oncology department under ain kind subcontractOutline of Likely Phase II Specific AimsContinuation of Phase I Research and Product Developmentnovel fully robotized system for batch processing all exposed CrystalBallsfor daily PSQAlaser CTscanningQA reportsannealing andampresetting overnightnovel designs of phantoms protocols software for HDD PSQA of SRSSBRTVMATIGRTMR linacand proton beam therapyincluding motion deformation control and gatingnovel design ofD printed anthropomorphic phantoms compatible with the new polymer gelsnovel design of phantoms protocols software for HDD machine QAfor MLCstablegantrycollimatoroutputnovel software for autogeneration of corrections to treatment plansnovel software for correlating HDD QA results with log filesin order to identify likely root causes of detected errors This project will improve radiotherapy and radiosurgery outcomes and patient safety while substantially lowering cancer care costs associated with avoidable recurrences and complications that lead to costly readmissionsdisabilitiesand premature deathwith all associated social costsThe product to be developed by the end of Phase II will routinely and cost effectively detect and correctprior to patient treatmentcommon errors that would be accumulated over the entire treatment planning and delivery processerrors that are normally hidden from existing radiation measurement systems and quality assurance protocols due to inadequate sampling of radiation dose data and patient positioning in bothD space and timeThe primary and unique advantage of the proposed newCrystal Ballsystem is its ability to detectprior to patient treatment and in a cost effective and time efficient mannerany clinically significant cumulative errors originating anywhere during the planning and delivery process and located anywhere in the treated volume of tissue